Combination of OipA, BabA, and SabA as candidate biomarkers for predicting Helicobacter pylori-related gastric cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Su, Yu Lin ^a   Huang, Hsiang Ling ^a   Huang, Bo Shih ^a   Chen, Po Chung ^b   Chen, Chien Sheng ^b   Wang, Hong Long ^c   Lin, Pin Hsin ^a   Chieh, Meng Shu ^a   Wu, Jiunn Jong ^d   Yang, Jyh Chin ^e   Chow, Lu Ping ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; BABA PROTEIN, HELICOBACTER PYLORI; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; OIPA PROTEIN, HELICOBACTER PYLORI; OUTER MEMBRANE PROTEIN; PEPTIDE; SABA PROTEIN, HELICOBACTER PYLORI;

BLOOD; CHEMISTRY; COMPLICATION; DUODENUM ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; ODDS RATIO; PATHOLOGY; PROTEIN MICROARRAY; PROTEOMICS; STOMACH TUMOR; UPREGULATION;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BIOMARKERS; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOASSAY; ODDS RATIO; PEPTIDES; PROTEIN ARRAY ANALYSIS; PROTEOMICS; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84994607543     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36442     Document Type: Article

References (60)

1. Covacci, A., Telford, J. L., Del Giudice, G., Parsonnet, J. & Rappuoli, R. Helicobacter pylori virulence and genetic geography. Science 284, 1328-1333 (1999).
2. Polk, D. B. & Peek, R. M. Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10, 403-414, doi: 10.1038/nrc2857 (2010).
3. Wroblewski, L. E., Peek, R. M. Jr. & Wilson, K. T. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 23, 713-739, doi: 10.1128/cmr.00011-10 (2010).
4. Uemura, N. et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345, 784-789, doi: 10.1056/ NEJMoa001999 (2001).
5. Atherton, J. C. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol 1, 63-96, doi: 10.1146/ annurev.pathol.1.110304.100125 (2006).
6. Kalali, B., Mejias-Luque, R., Javaheri, A. & Gerhard, M. H. pylori virulence factors: influence on immune system and pathology. Mediators Inflamm 2014, 426309, doi: 10.1155/2014/426309 (2014).
7. Yamaoka, Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 7, 629-641, doi: 10.1038/ nrgastro.2010.154 (2010).
8. Yamaoka, Y. & Graham, D. Y. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol 10, 1487-1500, doi: 10.2217/ fon.14.29 (2014).
9. Basso, D. et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 135, 91-99, doi: 10.1053/j.gastro.2008.03.041 (2008).
10. Shiota, S., Matsunari, O., Watada, M. & Yamaoka, Y. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol 5, 1885-1893, doi: 10.2217/fmb.10.135 (2010).
11. Memon, A. A., Hussein, N. R., Miendje Deyi, V. Y., Burette, A. & Atherton, J. C. Vacuolating cytotoxin genotypes are strong markers of gastric cancer and duodenal ulcer-associated Helicobacter pylori strains: a matched case-control study. J Clin Microbiol 52, 2984-2989, doi: 10.1128/jcm.00551-14 (2014).
12. Shiota, S., Matsunari, O., Watada, M., Hanada, K. & Yamaoka, Y. Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathog 2, 13, doi: 10.1186/1757-4749-2-13 (2010).
13. Lu, H., Hsu, P. I., Graham, D. Y. & Yamaoka, Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 128, 833-848 (2005).
14. Hamashima, C. Current issues and future perspectives of gastric cancer screening. World journal of gastroenterology 20, 13767-13774, doi: 10.3748/wjg.v20.i38.13767 (2014).
15. Boda, T. et al. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter 19, 1-8, doi: 10.1111/hel.12101 (2014).
16. di Mario, F. & Cavallaro, L. G. Non-invasive tests in gastric diseases. Dig Liver Dis 40, 523-530, doi: 10.1016/j.dld.2008.02.028 (2008).
17. Lehours, P. et al. Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun 72, 880-888 (2004).
18. Lin, Y. F. et al. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol Cell Proteomics 5, 1484-1496, doi: 10.1074/mcp.M600111-MCP200 (2006).
19. Peek, R. M. Jr., Fiske, C. & Wilson, K. T. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev 90, 831-858, doi: 10.1152/physrev.00039.2009 (2010).
20. Ibraghimov, A. & Pappo, J. The immune response against Helicobacter pylori-a direct linkage to the development of gastroduodenal disease. Microbes Infect 2, 1073-1077 (2000).
21. Tu, H. et al. Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scand J Gastroenterol 49, 259-266, doi: 10.3109/00365521.2013.869352 (2014).
22. Liu, J. et al. Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer. Sci Rep 4, 4143, doi: 10.1038/ srep04143 (2014).
23. Song, H. et al. A CagA-independent cluster of antigens related to the risk of noncardia gastric cancer: associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serology. International journal of cancer 134, 2942-2950, doi: 10.1002/ijc.28621 (2014).
24. Gao, L. et al. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res 69, 6164-6170, doi: 10.1158/0008-5472.can-09-0596 (2009).
25. Lin, L. L., Huang, H. C. & Juan, H. F. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 75, 3081-3097, doi: 10.1016/j.jprot.2012.03.046 (2012).
26. Wu, M. S., Chow, L. P., Lin, J. T. & Chiou, S. H. Proteomic identification of biomarkers related to Helicobacter pylori-associated gastroduodenal disease: challenges and opportunities. J Gastroenterol Hepatol 23, 1657-1661, doi: 10.1111/j.1440-1746.2008.05659.x (2008).
27. Huang, C. H. & Chiou, S. H. Clinical proteomics identifies potential biomarkers in Helicobacter pylori for gastrointestinal diseases. World journal of gastroenterology 20, 1529-1536, doi: 10.3748/wjg.v20.i6.1529 (2014).
28. Tan, H. T., Low, J., Lim, S. G. & Chung, M. C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276, 6880-6904, doi: 10.1111/j.1742-4658.2009.07396.x (2009).
29. Xu, Q. W. et al. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res 72, 6351-6361, doi: 10.1158/0008-5472.can-12-1656 (2012).
30. Ali, M. et al. Association between cag-pathogenicity island in Helicobacter pylori isolates from peptic ulcer, gastric carcinoma, and non-ulcer dyspepsia subjects with histological changes. World journal of gastroenterology 11, 6815-6822 (2005).
31. Maeda, S. et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 42, 338-343 (1998).
32. Shitara, K. et al. Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 15, 137-143, doi: 10.1007/s10120-011-0083-8 (2012).
33. Posselt, G., Backert, S. & Wessler, S. The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal 11, 77, doi: 10.1186/1478-811x-11-77 (2013).
34. Zhang, J., Qian, J., Zhang, X. & Zou, Q. Outer membrane inflammatory protein A, a new virulence factor involved in the pathogenesis of Helicobacter pylori. Mol Biol Rep, doi: 10.1007/s11033-014-3673-9 (2014).
35. Wen, S. & Moss, S. F. Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett 282, 1-8, doi: 10.1016/j. canlet.2008.11.016 (2009).
36. Rieder, G. et al. Role of adherence in interleukin-8 induction in Helicobacter pylori-associated gastritis. Infect Immun 65, 3622-3630 (1997).
37. Shigematsu, Y. et al. Interleukin-1beta induced by Helicobacter pylori infection enhances mouse gastric carcinogenesis. Cancer Lett 340, 141-147, doi: 10.1016/j.canlet.2013.07.034 (2013).
38. Yamada, S. et al. Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. World journal of gastroenterology 19, 2941-2949, doi: 10.3748/wjg.v19.i19.2941 (2013).
39. Dossumbekova, A. et al. Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms. J Infect Dis 194, 1346-1355, doi: 10.1086/508426 (2006).
40. Odenbreit, S. et al. Outer membrane protein expression profile in Helicobacter pylori clinical isolates. Infect Immun 77, 3782-3790, doi: 10.1128/iai.00364-09 (2009).
41. Lu, H. et al. Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains. J Biol Chem 282, 6242-6254, doi: 10.1074/jbc.M611178200 (2007).
42. Wen, S. et al. Expression of Helicobacter pylori virulence factors and associated expression profiles of inflammatory genes in the human gastric mucosa. Infect Immun 75, 5118-5126, doi: 10.1128/iai.00334-07 (2007).
43. Liu, J. et al. Association of presence/absence and on/off patterns of Helicobacter pylori oipA gene with peptic ulcer disease and gastric cancer risks: a meta-analysis. BMC infectious diseases 13, 555, doi: 10.1186/1471-2334-13-555 (2013).
44. Souod, N. et al. The study of the oipA and dupA genes in Helicobacter pylori strains and their relationship with different gastroduodenal diseases. Gastroenterology and hepatology from bed to bench 8, S47-S53 (2015).
45. Chen, M. Y., He, C. Y., Meng, X. & Yuan, Y. Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer. World journal of gastroenterology 19, 4242-4251, doi: 10.3748/wjg.v19.i26.4242 (2013).
46. Yamaoka, Y. Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease. Journal of infection in developing countries 2, 174-181 (2008).
47. Yamaoka, Y. et al. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut 55, 775-781, doi: 10.1136/ gut.2005.083014 (2006).
48. Sheu, B. S. et al. Interaction between host gastric Sialyl-Lewis X and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis B antigen. The American journal of gastroenterology 101, 36-44, doi: 10.1111/j.1572-0241.2006.00358.x (2006).
49. Suerbaum, S. & Josenhans, C. Helicobacter pylori evolution and phenotypic diversification in a changing host. Nature reviews. Microbiology 5, 441-452, doi: 10.1038/nrmicro1658 (2007).
50. Mini, R. et al. Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J Chromatogr B Analyt Technol Biomed Life Sci 833, 63-79, doi: 10.1016/j.jchromb.2005.12.052 (2006).
51. Portal-Celhay, C. & Perez-Perez, G. I. Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. Clin Sci (Lond) 110, 305-314, doi: 10.1042/cs20050232 (2006).
52. Zevering, Y., Jacob, L. & Meyer, T. F. Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Gut 45, 465-474 (1999).
53. Testerman, T. L. & Morris, J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World journal of gastroenterology 20, 12781-12808, doi: 10.3748/wjg.v20.i36.12781 (2014).
54. Lin, J. T., Wang, J. T., Wang, T. H., Wu, M. S. & Chen, C. J. Helicobacter pylori infection in early and advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese patients. Hepato-gastroenterology 40, 596-599 (1993).
55. Klaamas, K., Held, M., Wadstrom, T., Lipping, A. & Kurtenkov, O. IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. International journal of cancer 67, 1-5, doi: 10.1002/(sici)1097-0215(19960703)67:1< 1::aid-ijc1> 3.0.co;2-0 (1996).
56. Chen, P. C. et al. Antibody profiling of bipolar disorder using Escherichia coli proteome microarrays. Mol Cell Proteomics, doi: 10.1074/mcp.M114.045930 (2014).
57. Henjes, F. et al. Analysis of autoantibody profiles in osteoarthritis using comprehensive protein array concepts. J Proteome Res 13, 5218-5229, doi: 10.1021/pr500775a (2014).
58. Wang, J. et al. A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics Clin Appl 7, 378-383, doi: 10.1002/prca.201200062 (2013).
59. Tseng, C. W. et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics 11, 2423-2439, doi: 10.1002/pmic.201000449 (2011).
60. Messing, J., Niehues, M., Shevtsova, A., Boren, T. & Hensel, A. Antiadhesive properties of arabinogalactan protein from ribes nigrum seeds against bacterial adhesion of Helicobacter pylori. Molecules 19, 3696-3717, doi: 10.3390/molecules19033696 (2014).